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Many recent studies have demonstrated the efficacy of intense pulsed light (IPL) for the treatment 
of meibomian gland dysfunction (MGD); however, its effective treatment targets have not yet been 
elucidated. this study aimed to investigate the baseline characteristics associated with an improvement 
in symptoms after IPL treatment; to examine the course of change in inflammatory tear cytokines, 
meibomian gland function, and tear stability; and to investigate the correlation between cytokines and 
ocular surface parameters. thirty participants underwent three sessions of IpL treatment. During each 
examination, tear film lipid layer interferometry, meibography, tear meniscus height measurement, 
tear sampling, and slit-lamp examination were performed, and the Ocular Surface Disease Index (OSDI) 
questionnaire was administered. Meibum quality, meibum expressibility, lid margin abnormality, tear 
film break-up time (TBUT), ocular surface staining, and the OSDI significantly improved after treatment. 
Poor meibum expressibility and short TBUT were associated with greater recovery in the OSDI after 
IPL. Tear levels of IL-4, IL-6, IL-10, IL-17A, and TNF-α decreased after IPL, and IL-6, and TNF-α were 
correlated with the improvement in meibum expressibility. therefore, IpL treatment improved 
meibomian gland function, stabilized the tear film, and decreased ocular surface inflammation. Patients 
with obstructive MGD and tear instability were more likely to experience an improvement in ocular 
discomfort after IpL treatment.
Meibomian gland dysfunction (MGD) is a prevalent cause of evaporative dry eye, affecting more than 50% of the 
Asian population1. However, many patients do not benefit from currently available treatments such as lid hygiene, 
meibum expression, and anti-inflammatory therapy2.
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Concurrent improvement of ocular surface conditions observed in patients treated for rosacea of their face, 
led to the potential implementation of intense pulsed light (IPL) for the treatment of MGD3. IPL has been widely 
used in dermatology to treat various conditions such as rosacea, benign vascular lesions, and pigmented lesions4. 
It utilizes a noncoherent, polychromatic light source to yield selective photothermolysis, wherein a specific wave-
length of light is absorbed by a chromophore and converted into heat to destroy the target tissue4,5. Previous stud-
ies have reported favorable outcomes given the therapeutic effect of IPL in patients with MGD6–14. The potential 
mechanisms of action of IPL in MGD include the coagulation of telangiectasia, which may lead to a decrease in 
inflammation15, and the liquefaction of the viscous meibum and dilation of the clogged meibomian gland ducts 
caused by the heat energy11.
Tear cytokines have been reported to be elevated in dry eye and MGD, and to be correlated with symptoms 
and clinical parameters16,17. Therefore, a serial evaluation of the changes in tear cytokine levels and clinical assess-
ment throughout the sequential treatment period would help explain the anti-inflammatory effect of IPL, as well 
as in determining the correlation between inflammation and the clinical outcome. A recent study showed that IPL 
treatment can reduce the levels of tear inflammatory markers IL-17A and IL-6 in patients with MGD18. In addi-
tion, the altered levels of IL-6 in tears correlated with the changes in the number of meibomian glands producing 
a clear secretion from the lower lid after IPL treatment18. Although IL-17A and IL-6 are well known to play a role 
in the pathogenesis of dry eye, MGD is a multifactorial disorder accompanied by ocular surface inflammation, 
but its etiology and pathogenesis remain unknown. TNF-α is another pleiotropic proinflammatory cytokine that 
has been associated with dry eye disease (DED)19. Moreover, DED has been considered a Th1-dominant disease; 
however, reports have suggested that autoantibodies may be involved in the pathogenic mechanism20. Therefore, 
it would be useful to also investigate cytokines associated with the Th2 response.
In the current study, the proposed anti-inflammatory effect of IPL was further investigated by analyzing addi-
tional tear inflammatory cytokines other than those previously evaluated. In addition, the clinical signs that 
changed in correlation with the inflammatory cytokine levels were investigated. The clinical characteristics of 
patients who experienced the greatest alleviation of ocular discomfort after IPL treatment were also explored. 
Hence, we sought to identify the important clinical factors and inflammatory cytokines associated with the treat-
ment effect of IPL in patients with MGD.
Results
Clinical parameter changes and IPL. The mean scores (range) of meibum expressibility, lid margin 
abnormality, OSDI, and meibomian gland dropout were 2.9 (2–4), 3.5 (3–4), 58.2 (4.2–92.0), and 3.2 (2–5), 
respectively. The geometric means (range) of meibum quality score, ocular surface staining score, and TBUT 
were 3.4 (3–4), 1.8 (1–4), and 3.5 (0.5–9.0), respectively. Therefore, the subjects had moderate to severe MGD 
according to the clinical signs of MGD (meibum expressibility, lid margin abnormality, and meibomian gland 
dropout) and accompanying severe DED in terms of a short TBUT and high OSDI score.
The changes in clinical parameters over the time period of the three IPL sessions are outlined in Fig. 1. 
Meibum quality, meibum expressibility, and lid margin abnormality improved after IPL treatment, as shown 
by the decrease in their scores. TBUT increased and the ocular surface staining score decreased serially with 
Figure 1. Change in clinical parameters following each intense pulsed light treatment session in patients with 
meibomian gland dysfunction. (A) Meibum quality, (B) meibum expressibility, (C) lid margin abnormality, 
(D) tear film break-up time (TBUT), (E) ocular surface staining score using the Oxford scheme, and (F) Ocular 
Surface Disease Index (OSDI). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; Friedman test or repeated-
measure analysis of variance (ANOVA) with post-hoc multiple comparison analysis, comparing the value 
after each session to that of the baseline. Individual points and error bars represent the mean (B,C,F) or the 
geometric mean (A,D,E) and 95% confidence interval.
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treatment. The OSDI scores also decreased with IPL treatment. LLT, meibomian gland dropout, and tear menis-
cus area did not show any significant changes.
Clinical parameters associated with the improvement in symptoms. We constructed a multiple 
regression model to identify the individual clinical parameters associated with the improvement in the discom-
fort score, OSDI, after IPL treatment (Table 1). The OSDI score after three treatment sessions decreased from the 
baseline score by 18.2 for each additional meibum expressibility score at baseline and increased from the baseline 
by 4.5 for each additional second of TBUT at baseline (Table 1). Thus, the worse baseline meibum expressibility 
scores and shorter baseline TBUT were associated with a greater reduction in the OSDI score after three treat-
ment sessions. In addition, the OSDI score tended to decrease more in women than in men (Table 1).
Tear inflammatory cytokines and IPL. The tear cytokine levels were sequentially monitored to assess the 
anti-inflammatory effect of IPL. IL-4, IL-6, IL-10, IL-17A, and TNF-α levels showed a significant decrease over 
the time course (Fig. 2). However, the change in IL-2 level was not significant (P = 0.117, Kruskal-Wallis test). 
Although a slight increasing trend in IL-6, IL-17A, and TNF-α levels was observed after the third IPL session, the 
difference was not statistically significant (IL-6, P = 0.904; IL-17A, P = 0.394; TNF-α, P = 0.875).
Correlation between meibomian gland function and tear inflammatory cytokines. To inves-
tigate whether the change in tear cytokine levels was related to the change in meibomian gland function, a cor-
relation analysis was performed between the tear cytokine levels, IL-4, IL-6, IL-10, IL-17A and TNF-α, which 
decreased significantly after IPL treatment, and meibum quality and meibum expressibility. A positive correlation 
was observed between the changes in meibum expressibility and changes in IL-6 (r = 0.598, p = 0.02) and TNF-α 
(r = 0.755, p = 0.01) levels (Fig. 3). The correlation between the improvement in meibum expressibility and the 
decrease in IL-10 was significant in the correlation analysis (r = 0.533, p = 0.009), however became insignificant 
after the bonferroni correction (p = 0.09). Potential complications and adverse events, including uveitis and iris 
damage, did not occur in any of the patients.
Variable (Baseline value)
Unstandardized 
coefficient (B)
Standardized 
coefficient (β) P value
Meibum expressibility −18.2 −0.396 0.003
TBUT 4.5 0.453 0.007
Sex (female) −19.1 −0.396 0.019
Table 1. Multiple linear regression analysis of the association of the change in OSDI score with baseline clinical 
conditions. The change in the OSDI score is defined as the OSDI after the 3rd treatment session – the OSDI at 
baseline. Age (P = 0.950), meibum quality (P = 0.980), lid margin abnormality (P = 0.928), and ocular surface 
staining (P = 0.767) were excluded from the model by using the stepwise method. P value for the overall model 
is 0.002 and adjusted R2 is 0.368. OSDI = Ocular Surface Disease Index; TBUT = tear film break-up time.
Figure 2. Change in cytokine profiles following each intense pulsed light (IPL) treatment session as a ratio 
compared to the baseline. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; analysis of variance (ANOVA) 
(C,F) or Kruskal-Wallis test (A,B,D,E) with post-hoc analysis, comparing the value after each session to that 
of the baseline. Individual points and error bars represent the mean (C,F) or the median (A,B,D,E) and 95% 
confidence interval.
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Discussion
IPL treatment was applied to patients with moderate to severe MGD and severe DED. Among the clinical param-
eters that responded to IPL treatment (Fig. 1), meibum expressibility showed the strongest relationship with 
the improvement in the OSDI score when other parameters were statistically controlled (Table 1). Additionally, 
meibum expressibility correlated with multiple inflammatory tear cytokines, IL-6 and TNF-α, whose levels were 
shown to decrease with IPL treatment (Figs 2 and 3).
IPL treatment improved the clinical parameters associated with meibomian gland function, including mei-
bum quality, expressibility, and the lid margin abnormality score. A possible mechanism of action of IPL has 
been suggested as the local warming effect, which liquefies the inspissated meibum and encourages more regular 
outflow11. Previous studies have also reported improved meibum viscosity and oil flow score10 and a significant 
increase in meibomian gland expression8,12,14. The forced expression of meibomian glands after IPL treatment 
may also have contributed to the improvement in clinical parameters; however, previous studies have reported 
improved lipid layer grade7, improved meibomian gland secretion quality and expressibility9, increased TBUT7,9, 
and improvement in symptom scores7,9 after IPL treatment alone.
Improvement in the parameters related to meibomian gland function could improve the quality of the tear 
lipid layer and reinforce tear film integrity. In fact, TBUT and ocular surface staining improved after IPL treat-
ment, and this result was well correlated with the results of previous studies7,9,12–14. However, the stabilization of 
the ocular surface was not accompanied by an increase either in the tear meniscus area or in LLT of the tear film. 
A previous study also found no change in tear meniscus height after IPL treatment7, and another study reported 
no change in LLT after IPL treatment13. Therefore, improved meibum quality and expressibility possibly strength-
ened the tear film and prevented tear evaporation, without affecting the tear volume itself.
Increased LLT was associated with increased age and female sex, as well as hypersecretory MGD and lid mar-
gin inflammation in a previous report21. Thus, the quantified LLT is affected by demographic factors and other 
confounders, and may not directly reflect meibomian gland function. A previous report that showed lipid layer 
improvement after IPL treatment examined the pattern of the tear film by using a different interferometry device7, 
while the interferometry in our study automatically calculated the LLT of the lower part of the cornea. Thus, the 
automatically quantified LLT may not be able to accurately portray the lipid layer status throughout the ocular 
surface, and the lipid quality of the tear film, instead of the thickness itself, may be more important in ocular 
surface stabilization. Qualitative lipid change is known to occur in MGD, and the change in lipid composition 
interferes with the adherence of the outermost lipid layer to the intermediate aqueous component, thus contrib-
uting to tear film instability and vulnerability to evaporation22.
The improvement in clinical parameters was accompanied by a reduction in patient-reported symptoms, the 
OSDI, and this was in concordance with the findings of previous studies6–8,12,14. The OSDI has been proven a 
reliable and valid tool in discriminating the severity of DED23. Women and those with a greater number of unex-
pressible meibomian glands and shorter TBUT showed a significant degree of reduction in the posttreatment 
OSDI score (Table 1). This was consistent with the findings of a previous study, which reported that patients with 
initially worse meibomian gland expressibility showed greater improvement on the OSDI after IPL treatment12. 
Therefore, those with obstructive MGD with decreased meibum expressibility and tear film instability are most 
likely to experience an improvement in ocular discomfort after IPL treatment.
Tear cytokine assays provide evidence for the ocular surface inflammation. IL-6 and IL-17A were reported 
to decrease in tears of MGD patients after IPL treatment18. In the current study, IL-4, IL-6, IL-10, IL-17A and 
TNF-α, which are cytokines known to be associated with DED24,25, decreased significantly following IPL treat-
ment in MGD patients. The decrease in multiple tear cytokine concentration after IPL treatment may indicate that 
IPL was able to reduce inflammation which is one of the pathogenic mechanisms of MGD.
IL-6 and TNF-α are pleiotropic proinflammatory cytokines, which have been described as the key molecules 
in DED19,24. A previous report showed that IL-6 level was significantly increased in the tears of patients with DED, 
and it correlated with various ocular surface parameters, including TBUT, Schirmer test, and the keratoepithelio-
plasty score26. IL-17, whose level was also shown to be significantly increased in patients with MGD and DED25, is 
primarily produced by Th-17 cells and is known to increase the production of other inflammatory cytokines such 
as IL-6, TNF-α, IL-1, and IL-8, as well as the recruitment of leukocytes.
Although DED has been considered a Th1-dominant disease, evidence that autoantibodies may also be 
engaged in the pathogenic mechanism20 may explain our finding that the levels of IL-4 and IL-10, cytokines 
involved in the Th2 response, decreased after IPL treatment. IL-4 and IL-10 have previously been detected on the 
Figure 3. Scatter plot showing the correlations between the change in meibum expressibility and the change in 
the levels of tear cytokines IL-6 (A), TNF-α (B), and IL-10 (C). r = Spearman’s correlation coefficient.
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ocular surface of patients with DED24. IL-10 is predominantly an inhibitory cytokine that has multiple effects on 
immunoregulation, inflammation, and antibody production27. It is secreted not only by macrophages and Th2 
cells, but also by regulatory T cells (Treg). Treg cells have been shown to suppress ocular surface inflammation 
associated with DED28, and studies have demonstrated that a Th17 cell subset, previously mentioned as a primary 
effector cell in DED, counteracts the Treg-mediated suppression in DED29.
The improvement in meibum expressibility positively correlated with the reduction in the levels of multiple 
tear inflammatory cytokines, such as IL-6 and TNF-α (Fig. 3). This finding was consistent with that of a previous 
report, which showed that the change in IL-6 level after IPL treatment correlated with the change in meibomian 
gland secretion in the lower lid18.
The probable mechanism behind the relationship between meibum expressibility and tear inflammatory 
cytokines could be explained by the following pathogenesis of MGD. Increased meibum viscosity and reduced 
expression may arise from the changes in meibum composition30. The stasis of the meibum can promote bacte-
rial growth, which may then lead to the increased release of esterases and lipid-degrading lipases. The increased 
enzyme activity not only increases meibum melting temperature, but also generates free fatty acids that can lead 
to hyperkeratinization and inflammation31. These changes in lipid composition lead to further meibomian gland 
obstruction, ocular surface instability, and increased tear evaporation, contributing to the development of DED 
and patient discomfort. Therefore, ocular surface inflammation and meibomian gland expressibility are inter-
actively involved in the cascade of the pathophysiologic mechanism of MGD, and our results suggest that the 
improvement in inflammation and meibum expressibility after IPL treatment is mutually inclusive, and that they 
might be important therapeutic targets of IPL treatment in patients with MGD.
The limitations of this study include a small sample size, lack of a control group, and a risk of the placebo effect 
and investigator bias. However, a previous paired-eye study showed that IPL treatment greatly improved tear 
film quality and reduced dry eye symptoms than did a placebo treatment7. The follow-up period after treatment 
termination was short. Hence, further investigation is needed to assess the long-term effectiveness and safety of 
IPL treatment. Future studies with larger sample sizes will be helpful in replicating and extending our findings. 
Additionally, it would have been helpful if the extent of lid margin vascularity was graded and its association with 
tear cytokines was evaluated, since one of the main mechanisms of action of IPL is coagulation of the superficial 
vessels. Furthermore, the clinical examinations were performed by one investigator, however we used the stand-
ardized grading scales reported by the International Workshop on Meibomian Gland Dysfunction32. Therefore, 
the measurement quality of the acquired data is less likely to be compromised.
Conclusions
Patients with low meibum expressibility and tear film instability experienced greater improvement in symptoms 
after IPL treatment. The improvement in meibum expressibility was also associated with a decrease in tear inflam-
matory cytokine levels. Therefore, meibum expressibility improvement might be a good therapeutic target of IPL 
treatment in patients with MGD and DED, and could be an indicator of ocular surface inflammation during IPL 
treatment.
Methods
patient selection. This prospective study adhered to the tenets of the Declaration of Helsinki and was 
approved by the Severance Hospital Institutional Review Board, Seoul, South Korea (1-2016-0010). All partici-
pants agreed and signed the written informed consent prior to enrollment. The study was registered at the Clinical 
Research Information Service (CRIS) under the registration number KCT0003051 (06/07/2018).
Participants over 19 years of age and diagnosed with moderate or severe MGD at Severance Hospital, Seoul, 
Korea, were screened for eligibility. MGD was staged according to the severity of symptoms, including ocular 
discomfort, and clinical signs, including lid margin features, meibum secretion, meibum expressibility, and ocular 
surface staining2. Participants were enrolled if they satisfied the following criteria for MGD staging. Moderate 
MGD was defined by moderate symptoms and MGD clinical signs (plugging and vascularity of the lid margins, 
meibum quality grade 2–3, and expressibility grade 3), and mild to moderate ocular surface staining (grade ≥ 1). 
Severe MGD was diagnosed on the basis of pronounced symptoms with limitation of daily activities, severe MGD 
signs (dropout, displacement of the lid margins, meibum quality grade ≥ 3, and expressibility grade 4), increased 
ocular surface staining (grade ≥ 1), and inflammatory signs (conjunctival hyperemia and phlyctenules). Patients 
with (1) Fitzpatrick skin type V or VI; (2) active allergy, infection, or ocular surface inflammatory disease unre-
lated to dry eye or MGD; (3) systemic diseases or medication use in which light therapy is contraindicated; (4) 
uncontrolled systemic disease; (5) ocular surgery history within 6 months before study initiation; (6) contact lens 
use; (7) tattoos, semipermanent makeup, and pigmented lesions in the treatment area; and (8) clinical skin treat-
ments within 2 months were excluded, as were (9) pregnant patients and nursing mothers.
The eye with a higher stage of MGD was chosen for the study. If the MGD stage was equivalent in both the 
eyes, the right eye was enrolled. Thirty eyes of 30 patients who completed three sessions of IPL and four clinical 
examinations and tear sample collection were included in the analysis. The mean age of the patients was 51 ± 18 
years, and 76.7% of them were women.
treatment technique. Patients received three sessions of IPL treatment at 3 week intervals. All treatment 
adhered to the Toyos protocol6. IPL-Aid Disposable Eye Shields (Honeywell Safety Products, Smithfield, RI, USA) 
were placed to protect the participants’ eyes. A cooling gel was generously applied to the treatment area, and 
homogenously sculpted light pulses of 590-nm wavelength and intensity ranging from 12 to 14 J/cm2 were deliv-
ered to the periocular skin inferior and lateral to the eye by using the M22 IPL machine (Lumenis Ltd., Israel). A 
590-nm filter was selected to allow for selective photothermolysis of hemoglobin within the blood vessels, which 
had an optimal absorption range of 577–600 nm33. The fluence was initially set at 13 J/cm2, a previously reported 
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setting for the treatment of rosacea and telangiectasia34, and was adjusted individually according to the patients’ 
tolerance and comfort. Approximately 15 overlapping pulses were applied from the preauricular area, across 
the cheeks and nose to the contralateral side, and bordering close to the inferior boundary of the eye shields to 
ensure the light pulses were delivered as close as possible to the lower eyelids. After the initial pass was completed, 
more ultrasound gel was applied, and the treatment was repeated for a second pass. After IPL treatment, manual 
expression of the meibomian glands of both the upper and lower eyelids was performed using meibum expressor 
forceps. The patients were instructed to maintain lid scrub and to use artificial tears during the treatment period.
Clinical assessments. The clinical assessments were executed at baseline, at each separate treatment session, 
and at 3 weeks after the last session. All evaluations were performed before the IPL treatment at every visit. The 
order of the examinations was such that the influence of a preceding test on the subsequent test was minimized. 
All patients underwent tear film lipid layer interferometry, followed by tear meniscus area measurement by using 
anterior segment optical coherence tomography. Thereafter, tear sampling was performed, followed by slit-lamp 
examinations, including a fluorescein tear break-up time (TBUT), measurement of ocular surface staining, and 
examination of the lid margin and meibomian glands. All clinical examinations were undertaken by a single 
masked investigator (M.C.), and the IPL treatment was performed by another investigator (K.Y.S.).
Lipid layer thickness (LLT) measurement and meibography were performed using an interferometer 
(LipiView®, TearScience Inc, Morrisville, NC, USA) as previously described35. LLT is derived from the reflected 
tear film image, and is calculated as interferometric color units (ICUs), where 1 ICU represents approximately 
1 nm. The maximum LLT that can be measured is 100 nm. The lower eyelids were everted to obtain infrared 
images of the meibomian glands. Meibomian gland dropout was scored on a 1 to 5 meiboscale, graded according 
to the area of gland loss (1, 0%; 2, < 25%; 3, 25–50%; 4, 51–75%; and 5, > 75%)36.
A 3-mm vertical image at the middle of the lower eyelids was scanned using Fourier-domain optical coher-
ence tomography (RTVue; Optovue, Inc., Fremont, CA, USA) to measure the area for the lower tear meniscus37. It 
was defined as the area enclosed by the boundaries of the tear meniscus, cornea, and lower palpebral conjunctiva.
TBUT was measured by applying a fluorescein-impregnated strip (Haag-Streit, Koeniz, Switzerland) to the 
inferior palpebral conjunctiva. The mean time of three attempts was calculated. Thereafter, the Oxford scheme 
was used to grade corneal and conjunctival staining from 1 to 638.
Firm digital pressure was applied to the five central glands of the lower lid to evaluate meibum expressibility 
and quality. Meibum expressibility was scored as 1, all 5 glands; 2, 3–4 glands; 3, 1–2 glands; and 4, 0 glands39, and 
meibum quality was scored as 1, clear; 2, cloudy; 3, cloudy and particulate; and 4, inspissated, and was recorded as 
the highest grade expressed by the examined glands40. The lid margin abnormality score was calculated as the sum 
of the following four parameters: vascular engorgement, meibomian gland orifice plugging, irregularity of the lid 
margin, and mucocutaneous junction displacement (each parameter was given 1 point if present)41. Subjective 
symptoms were assessed using the Ocular Surface Disease Index (OSDI)23.
Tear sample collection and cytokine analysis. Tear samples were collected from all patients at every 
visit. We instilled 30 µL of phosphate-buffered saline into the inferior conjunctival fornix, and then collected 20 µL 
of the unstimulated tear fluid and buffer by using a micropipette. The samples were individually collected, each 
allocated into separate 0.5-mL Eppendorf tubes (Eppendorf, Fremont, CA, USA), and were preserved at a very 
low temperature of −70 °C until further analysis.
The levels of tear cytokines were analyzed using a multiplex bead-based immunoassay (BDTM Cytometric 
Bead Array Human Soluble Protein Flex Set; BD Biosciences, San Jose, CA, USA). The cytokines IL-2, IL-4, IL-6, 
IL-10, IL-17A, and TNF-α were investigated. The tear samples were incubated with antibody-coated capture 
beads and the detector antibody-phycoerythrin agent at room temperature for 3 hours. The samples were washed 
to remove the unbound antibodies. Flow cytometry was performed, and FCAP ArrayTM v3.0 (BD Cytometric 
Bead Array software; BD Biosciences) was used to interpolate the sample concentrations by comparison to a 
standard curve and to analyze the data.
statistical analysis. Prospective power calculations for sample size requirements were conducted before 
study initiation. A minimum of 25 participants was required to detect an effect size of 0.6 to achieve a power of 
80% and a two-sided statistical significance level of 5%. To assess the time course changes in the clinical param-
eters over the three treatment sessions, repeated-measure analysis of variance (ANOVA) or Friedman test was 
applied depending on the normality of data. Those with normal distribution were analyzed using a parametric 
test, and the arithmetic mean was calculated. If the data were not normally distributed, logarithmic transfor-
mation of the dataset was performed, and the geometric mean was calculated. If significant differences were 
observed, the Bonferroni post-hoc test or Dunn’s test for multiple comparisons was performed to compare the 
baseline and posttreatment data at individual time points. Multiple regression models were constructed to iden-
tify baseline clinical parameters associated with the changes in the OSDI scores after treatment. The tear cytokine 
data were transformed into ratios by using the baseline value as the reference. The outliers were identified using 
robust regression followed by the outlier identification method and were excluded. Thereafter, ANOVA or the 
Kruskal-Wallis test was used to compare multiple variables, including the baseline and sequential measure-
ments at each visit after the corresponding treatment session. If significant differences were observed, Dunnett’s 
or Dunn’s post-hoc test was performed to compare the baseline and posttreatment values after each session. 
Spearman’s rank-order correlation was used to investigate the association between the change in tear cytokine lev-
els and the improvement in meibomian gland function, and Bonferroni correction was conducted. The data were 
transformed into ratios of the results after the final session to the baseline value, and these ratios were used in 
the analysis. Statistical analyses were conducted using IBM SPSS Statistics for Windows/Macintosh, Version 23.0 
(IBM Corp., Armonk, NY, USA) and GraphPad Prism version 7.0 (GraphPad Software Inc., La Jolla, CA, USA).
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Data Availability
The datasets generated and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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